The US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) for Abbott’s new molecular point-of-care test to detect coronavirus (Covid-19).
The latest test runs on the company’s ID NOW platform and delivers positive results in five minutes and negative results within 13 minutes.
The ID NOW platform is a rapid, instrument-based, isothermal system used for the qualitative detection of infectious diseases.
